The tributyrin lipid emulsion was proved to be able to bind to low-density lipoprotein (LDL) in vitro. The aim of this study was to investigate the pharmacokinetics of the emulsion in vivo and the cellular activity in vitro. The pharmacokinetics of tributyrin and its metabolite, butyrate, was evaluated in male Wistar rats after administration with pure tributyrin or tributyrin emulsion. After oral administration, maximal plasma concentration (C max ), time to reach maximal plasma concentration (T max ), and elimination half-life (T 1/2 ) of butyrate were 87.6 M and 25.3 and 63.0 min, respectively, for the pure tributyrin compared with 1344.5 M and 8.5 and 19.8 min for the 10% (v/v) tributyrin emulsion. C max and mean residence time of tributyrin were 2.74 M and 87.9 min and 4.2 M and 132.0 min for pure tributyrin and 10% emulsion, respectively. The bioavailabilities of the pure tributyrin versus tributyrin emulsion were 15.3 versus 65.7% and 34.9 versus 64.5% calculated from butyrate and tributyrin, respectively. After the rats were treated with 17␣-ethynylestradiol (an LDL receptor up-regulator), the distribution volumes calculated from both butyrate and tributyrin were significantly increased after oral administration or infusion of the 10% tributyrin emulsion. The increased distribution volume after coadministration with a LDL receptor up-regulator suggested the increased uptake of tributyrin/butyrate by tissues with increased expression of LDL receptors. The selective uptake of the emulsion by the cellular LDL receptors was further confirmed by testing the cellular viability in the presence of competing LDL. The viable cells can reach 92% of control at IC 50 in Caco-2 and 77% in HepG2 incubated with emulsion in the presence of LDL.
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Low-density lipoprotein (LDL) is the major transport protein for cholesterol in human plasma. LDL is a spherical particle with a diameter of 20 to 25 nm. Each LDL particle contains cholesteryl esters in its core, which is surrounded by a hydrophilic coat composed of phospholipids, cholesterol, and one molecule of hydrophobic protein called apolipoprotein B-100 (apoB-100), the ligand for binding of the lipoprotein to specific receptors on the cell plasma membrane. After binding to the receptors, LDL is internalized via receptormediated endocytosis and degraded in lysosomes (Brown and Goldstein, 1986) , and the cholesterol is liberated for use in the synthesis of steroid hormones and new plasma membranes. In the rapidly proliferating malignant cells, the increased need of cholesterol for new membrane synthesis may result in overexpression of the LDL receptor (Ho et al., 1978; Gueddari et al., 1993; Leppälä et al., 1995; Maletinska et al., 2000; Sviridov et al., 2003) , which allows greater uptake of the lipoprotein by the neoplastic cells. Several investigators showed the uptake of LDL-drug complexes by malignant cells, leading to the possibility of using LDL as drug carrier in cancer chemotherapy (Maranhã o et al., 1994; Shawer et al., 2002; Chung and Wasan, 2004) . This would increase the antineoplastic effects while reducing the toxic effects upon normal cells. However, the native LDL is difficult to obtain and handle, so its introduction into clinical practice would be rather problematic. In contrast, lipid emulsion, which structurally resembles the lipid portion of the native LDL, can acquire apoB or apolipoprotein E (apoE) in plasma (Wilson et al., 1991; Maranhã o et al., 1994 Maranhã o et al., , 2002 Shawer et al., 2002; . The modified lipid emulsion particle enables it to be taken up by the cell via the LDL receptormediated pathway.
Tributyrin, a prodrug of butyrate with a half-life of approximately 6 min has more favorable pharmacokinetic properties and is better tolerated when compared with butyrate (Planchon et al., 1993) . Liquid tributyrin-filled gelatin capsules were administered orally, resulting in millimolar concentrations of butyrate both in plasma and inside the cell (Conley et al., 1998) . In the in vitro study, tributyrin by itself was found able to induce growth inhibitory and differentiating effects on carcinoma cells and showed even more potent activity than butyrate (Heerdt et al., 1999; Clarke et al., 2001; Schroder and Maurer, 2002; Yan and Xu, 2003) . It has also been shown to be an effective antitumor agent in combination with other agents in vitro (Witt et al., 2000; Gaschott et al., 2001 ).
In our previous paper , we proved that the lipid emulsion of tributyrin can bind with LDL in plasma. The purpose of the present work was to determine the pharmacokinetics of the emulsion in rats. Thus, we also performed the uptake study of lipid emulsion of tributyrin in Caco-2 and HepG2 cells, which have been reported to express up-regulated LDL receptors (Sviridov et al., 2003) .
Materials and Methods
Drugs and Chemicals. Tributyrin (99%) was a product of Kasei Kogyo Co. Ltd. (Tokyo, Japan). Lipoid E80 (containing 80% phosphatidylcholine) was obtained from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol (99%) and cholesteryl oleate (Ͼ98%) were all obtained commercially from Sigma-Aldrich (St. Louis, MO). Minimum essential medium was purchased from Invitrogen (Carlsbad, CA). Minimum essential medium nonessential amino acid, antihuman ␤-lipoprotein, and anti-goat IgG FITC conjugate were obtained from Sigma-Aldrich. All other chemicals were of reagent grade, and Milli-Q (Millipore Corporation, Billerica, MA) water was used throughout the experiment.
Animals. Adult male Wistar rats weighing 200 to 300 g were used. The rats were obtained from Laboratory Animal Center (National University of Singapore) at least 1 week before the experiments, and they were housed in a temperature-controlled room (22 Ϯ 2°C) with a light cycle of 12 h. The lights were on from 8:00 AM to 8:00 PM, during which time all of the experiments were conducted. The animals had free access to standard laboratory chow and tap water, unless otherwise stated.
Preparation of Tributyrin Emulsion. The emulsion was prepared according to the procedures developed by our previous study . In brief, after Lipoid E80, cholesterol, and cholesteryl oleate (65.8:13.7:20.5, w/w) were dissolved in chloroform, the solvent was evaporated and the residue was placed in desiccator overnight. The dry residue was fully suspended in water, and the obtained dispersion was added to tributyrin. The tonicity of the emulsion prepared was adjusted with glycerol. The mixtures were then sonicated using a probe sonicator (Sonics and Materials Inc., Newtown, CT), with the probe placed vertically in the center of the mixture. The sample container was cooled in an ice bath during sonication to minimize the heat generated. Sonication was carried out for 20 min with a 1-s pulse at a constant 35 W. The pH value of the emulsion was adjusted to pH 7.0 with 1 M NaOH. The emulsion prepared would have a particle size of 230 to 250 nm and a potential of Ϫ40 to Ϫ50 mV.
Pharmacokinetic Experiments. All animal procedures were approved by the Institutional Animal Care and Use Committee (National University of Singapore). At least 1 day before the experiments, the rats underwent surgery for the implantation of vascular cannulas. The right jugular vein was exposed and cannulated with a heparinized polyethylene-50 tube for blood sampling. The tip of the cannula was advanced to the right atrium of the heart. When intravenous administration was required, the left femoral vein was also exposed and cannulated with a heparinized polyethylene-10 tube, which was advanced to the inferior vena cava. With oral route of administration, the femoral vein was left uncannulated. The cannulas were then passed under the skin and fixed near the base of the neck.
The pharmacokinetics of tributyrin and its metabolite, butyrate, was evaluated in male Wistar rats after administration with pure tributyrin or tributyrin emulsion at the dose of 2 g/kg. Each dose of tributyrin was calculated on the basis of the fasted body weight of individual rat. Oral doses were given by a 1.5-inch, 18-gauge, and curved gavage needle, and infusion was delivered by Terufusion syringe pump TE-331 (Terumo, Tokyo, Japan) for 2 h. To confirm the effective binding of the lipid emulsion particles to the specific LDL receptors in vivo, pharmacokinetics of tributyrin was also evaluated in rats previously treated subcutaneously for 5 days with 17␣-ethynylestradiol, a compound that is known to up-regulate the activity of the LDL receptors in tissues (Chao et al., 1979) .
Blood samples (200 l) were drawn into a heparinized syringe via the jugular vein cannula. Samples were obtained at 0 (2-10 min before drug administration), 5, 10, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 240 , and 360 min after oral dosing. For infusion, samples were obtained at 30, 60, 90, and 120 min during infusion and 5, 10, 15, 30, 45, 60, 90, 105 , and 120 min after infusion. The collected blood volume was replaced with 200 l of warmed saline after each sample. The blood samples were stored in vials with phenylmethylsulfonyl fluoride in ice bath, and the plasma was separated within 1 h. The separated plasma was stored at Ϫ80°C and analyzed within 7 days using the gas chromatography-mass spectrometry method reported previously .
Pharmacokinetic Analysis. The plasma concentration-time profiles after oral administration were characterized by the following polyexponential equation,
where C(t) is the plasma concentration of drug at time t and A i and i are the coefficients and the exponents of the equation, respectively. The plasma concentration-time profiles after infusion were characterized by another two polyexponential equations,
where T is the duration of the infusion. The plasma data were modeled using WinNonlin version 4.1 pharmacokinetic software (Pharsight, Mountain View, CA) to calculate pharmacokinetic parameters of pure tributyrin and tributyrin emulsion from the plasma concentrations of both butyrate and tributyrin. When fitting to compartment model, the goodness of fit and the most appropriate model were determined by assessing the randomness of the scatter of actual data points around the fitted function and by using Akaike's information criterion (Akaike, 1976) and coefficient of variation percentage. The butyrate and tributyrin data from oral administration of pure tributyrin or tributyrin emulsion were best described with a one-compartmental model and noncompartmental model, respectively. Both the butyrate and tributyrin data from infusion of tributyrin emulsion were analyzed by one-compartmental model. The area under the curve (AUC) and total clearance (CL) were estimated through the noncompartmental method. AUC was calculated using the trapezoidal method. The mean residence time, bioavailability (F; using the average AUC of the intravenous data as the reference
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value), and volume of distribution (V) were calculated using standard formulas (Rowland and Tozer, 1995 To detect the in vitro apoptotic activity, DNA fragmentation assay was performed on both Caco-2 and HepG2 cells treated with the respective pure tributyrin and the tributyrin emulsion, according to a previously described procedure with minor modification (Herrmann et al., 1994) . Following incubation with 4 M pure tri-butyrin or tributyrin emulsion at 37°C for 96 h, the adherent and nonadherent cells were harvested after centrifugation. The harvested cells were washed with phosphate-buffered saline (PBS), and the cell pellets were treated with 3 ml of lysis buffer (1% Nonidet P-40 in 20 mM EDTA and 50 mM Tris-HCl, pH 7.4) at 37°C overnight. The supernatant was brought to 1% SDS and treated for 2 h with 0.5 mg/ml RNase at 56°C following digestion with 0.25 mg/ml proteinase K for at least 2 h at 37°C. After the addition of 0.5 volumes of 10 M ammonium acetate, the DNA was precipitated with 2.5 volume of isopropanol at Ϫ20°C overnight. DNA was collected and thoroughly rinsed with 15 ml of 70% ethanol for 2 h followed by centrifugation for 20 min at 14,000 rpm. The pellet was dried in a SpeedVac to remove the residual ethanol. DNA was dissolved in 25 l of TE buffer (10 mM Tris-HCl and 1 mM EDTA, pH 8.0) at 37°C overnight and run for gel electrophoresis on 1% agarose gel in TAE buffer (40 mM Tris-HCl, 20 mM acetic acid, and 1 mM EDTA, pH 7.8) with 0.5 g/ml ethidium bromide at 100 volts for 1 h.
LDL Receptors in Caco-2 and HepG2 Cell Lines. To prepare for the studies of tributyrin emulsion growth inhibition on neoplastic cells, the presence of LDL receptors was first investigated in Caco-2 and HepG2 cell lines. LDL receptors in these two cell smears were detected by the immunofluorescence technique with the following steps: the cells were cultured up to semiconfluency in culture dishes with coverglasses. After fixation with 4% (w/v) paraformaldehyde in PBS for 15 min at room temperature, the smears were incubated in 3% (w/v) bovine serum albumin (BSA), pH 7.5, for 1 h at room temperature to block unspecific binding of the antibodies. Goat IgG anti-human LDL receptor (1:50) in 1% (w/v) BSA, pH 7.5, then was incubated with smears at 4°C overnight followed by incubation with anti-goat IgG FITC conjugate (1:50) in 1% (w/v) BSA, pH 7.5, for 60 min at room temperature. After each step, the smears were washed with PBS, and finally, the smears were mounted in DABCO mounting medium (50% glycerol in PBS). The LDL receptor stained with FITC was observed under fluorescence microscope with blue filter (excitation: 330 -380 nm; emission: 420 nm). Negative control smears were performed in the same cell lines by omitting the primary antibody.
Growth Inhibition in Caco-2 and HepG2 Cell Lines. For determining cell proliferation, the viable cell numbers were counted using MTT assay. 10 4 cells were grown in 96-well microtiter plates. After an incubation time of 24 h at 37°C in an atmosphere containing 5% CO 2 , the cells were incubated in the medium with tributyrin concentrations ranging from 0.1 to 4 mM using tributyrin solution (tributyrin was first dissolved in dimethyl sulfoxide and then diluted with culture medium. The final concentration of dimethyl sulfoxide in the cell culture was Ͻ0.2% v/v) or tributyrin emulsion for 48 h. After that, 100 l of 0.5 mg/ml MTT in PBS was added to each well. The microtiter plate was incubated for another 2 h before measuring absorbance at 590 nm of the samples with microtiter plate reader (Spectrofluor; Tecan, Salzburg, Austria). The cell viability of each well (expressed as survival index) was determined using the following equation.
The 50% inhibitory concentration (IC 50 ) was determined as the drug concentration was required to inhibit 50% of the cell growth.
Competitive Uptake of Lipid Emulsion with LDL. This experiment was performed with Caco-2 and HepG2 cells as described above but with the addition of increasing amounts of native human LDL to each well of microtiter plate. The concentration of tributyrin emulsion was kept constant at 0.75 mM for Caco-2 and 1.0 mM for HepG2 in each well. The concentrations of native LDL ranged from 10 to 100 g/ml. After a 48-h incubation, the cell viability of each well was determined using MTT assay as described above.
Results

Pharmacokinetics of Butyrate and Tributyrin after
Oral Administration. The plasma concentration-time profiles of butyrate after oral administration of pure tributyrin or 10% emulsion of tributyrin to the healthy rats or rats treated with 17␣-ethynylestradiol are illustrated in Fig. 1A . Key pharmacokinetic parameters were calculated from these data and are presented in Table 1 . The maximal plasma concentration (C max ) and first-order absorption rate constant (K a ) of butyrate concentration from oral administration of 10% tributyrin emulsion were significantly higher than those from administration of pure tributyrin to the healthy group. In addition, the AUC 0 -360 for oral administration of pure tributyrin was only 20.1% of that for administration of emulsion to healthy rats. The results suggest that the emulsion prepared has the ability to enhance the oral absorption of tributyrin. The C max and AUC of butyrate concentration after oral administration of emulsion to the treated rats were significantly lower than that of the healthy rats. The CL and volume of distribution of tributyrin after administration of emulsion to the treated rats were 4.8-and 3.0-fold higher than those of the healthy rats. Because 17␣-ethynylestradiol was reported to up-regulate the activity of the LDL receptors in tissues (Chao et al., 1979) and the tributyrin emulsion has the ability of binding to LDL , the higher values of CL and volume of distribution in the treated rats were possible due to higher uptake of tributyrin in the form of emulsion and the consequent metabolism of the compound in these tissues.
The faster time to reach maximal plasma concentration (T max ) and higher AUC of tributyrin attained by the 10% emulsion when compared with the pure tributyrin ( Fig. 1B;  Table 1 ) indicate that the emulsion can enhance the oral absorption of tributyrin. However, after administration of the 10% emulsion, the concentration of tributyrin decreased to 11.9% of C max within 30 min in healthy rats, whereas the concentration after administration of the pure tributyrin dropped slowly after C max (Fig. 1B) . In comparison with the pure drug, the 10% emulsion achieved much higher butyrate concentration before 105 min in the healthy rats (Fig. 1A) . The results further illustrated the enhanced absorption of tributyrin in emulsion, leading to the formation of more butyrate after hydrolysis during the absorption process and in the blood circulation (O'Connor and Bailey, 1988) . After the rats were treated with 17␣-ethynylestradiol, an LDL receptor up-regulator, the tributyrin clearance after administration of the emulsion was increased by 3.3 times and the volume of distribution increased by 7.1 times; whereas the AUC 0 -360 was reduced by 4.6 times. These results suggested that the induction of LDL receptors in the tissues enhanced the uptake of tributyrin in the form of lipid emulsion. 
Downloaded from
Pharmacokinetics of Butyrate and Tributyrin after Infusion. During the continuous infusion of emulsion to healthy rats for 2 h, the butyrate concentration from the 10% emulsion remained steady and fluctuated within 7.0% (relative standard deviation), which indicated that the elimination rate was roughly equal to the infusion rate. In contrast, the butyrate concentrations from the 5% emulsion decreased by 70.9% and concentrations from the 15% emulsion increased by 32.2%, respectively ( Fig. 2A) . The results suggest that continuous infusion of 10% tributyrin emulsion can maintain a steady plasma butyrate concentration in the healthy rats. The rapid decline in butyrate concentration 
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at ASPET Journals on April 15, 2017 jpet.aspetjournals.org despite continuous infusion of 5% emulsion could be due to rapid uptake of the drug by the peripheral tissues and metabolic organs at a rate faster than the infusion rate. With an infusion of 15% emulsion, when these sites presumed to be the LDL receptors were saturated, continuous infusion caused a substantial increase in the butyrate concentration. The decrease in the butyrate concentration during infusion of 10% tributyrin emulsion to the rats pretreated with the LDL receptor inducer indicated faster elimination of tributyrin from the blood through higher uptake of emulsion by tissues with up-regulated expression of lipoprotein receptors. The significant differences (p Ͻ 0.05) in the clearance and distribution volume between the healthy and the pretreated rats infused with 10% emulsion suggested that 17␣-ethynylestradiol could enhance the uptake of the tributyrin emulsion at both the peripheral and clearance sites ( Table 2 ). Despite that AUC values for butyrate concentration were found to be proportional to the increasing doses of the 5, 10, and 15% emulsions (r 2 Ͼ 0.99), the extrapolated line of the plot of the AUC against dose was significantly far away from the zero intercept (p Ͻ 0.05) (figure not shown). The volume of distribution and clearance after infusion of the 10 and 15% tributyrin emulsion were also lower than that after the 5% emulsion, indicating that nonlinear kinetics was involved in the disposition and elimination of tributyrin during infusion (Table 2). It may be noted that the time to reach steady state for drugs with nonlinear kinetics is affected by the dosing rate in addition to the metabolic rate and volume of distribution of the drug (Mehvar, 2001) . That could be the reason for the 5, 10, and 15% emulsion to have different steady-state profiles.
During infusion of the 10 and 15% emulsion to the healthy rats and 10% emulsion to the treated rats, the tributyrin concentrations fluctuated minimally within 11.2, 10.4, and 8.0%, (Fig. 2B) . In the respective healthy group receiving the emulsion infusion, a peak in the tributyrin plasma concentration always appeared after the infusion was terminated. This phenomenon could be due to the release of the drug from the LDL receptor binding sites back to the blood circulation after termination of the infusion. This phenomenon was absent in the rats treated with the LDL receptor up-regulator, probably because of much higher tissue binding capacity to lipid emulsion in tissues (Fig. 2B) .
DNA Fragmentation Assay. Internucleosomal DNA degradation is a very specific event in apoptosis, leading to DNA fragmentation. To confirm that apoptotic activity of tributyrin was not affected by formulating it into a lipid emulsion, DNA fragmentation assay was conducted with both pure tributyrin and tributyrin emulsion on Caco-2 and HepG2 cell lines. The DNA from Caco-2 and HepG2 cells treated with either pure tributyrin or tributyrin emulsion displayed the characteristic internucleosomal ladder of DNA fragments (Fig. 3) . In contrast, the control Caco-2 and HepG2 cells showed no DNA fragments. The results suggest that tributyrin in the form of emulsion still possesses the apoptotic activity on Caco-2 and HepG2 cells.
LDL Receptors in Caco-2 and HepG2 Cell
Lines. An intense immunoreaction was observed in both Caco-2 and HepG2 cells stained with the antibody specific to the LDL receptors, indicating the presence of the receptors in these two cell lines (Fig. 4) . Omitting the primary antibody resulted in a negative reaction in these cells, confirming the specificity of the reaction (data not shown). This finding supported the previous report that both Caco-2 and HepG2 expressed the mRNA of LDL receptor (Sviridov et al., 2003) .
Growth Inhibition in Caco-2 and HepG2 Cell Lines. Growth inhibition studies were performed with Caco-2 and HepG2 cells. Pure tributyrin and tributyrin emulsion were tested at increasing concentrations of 0.1 to 4 mM. Figure 5A shows the inhibitory effect of increasing concentrations of pure tributyrin and tributyrin emulsion on Caco-2 cells after a 48-h exposure. The IC 50 for pure tributyrin and tributyrin emulsion were 0.90 and 0.75 mM, respectively. Figure 5B shows the inhibitory effect of increasing concentrations of pure tributyrin and tributyrin emulsion on HepG2 cells. In this cell line, the IC 50 were 1.6 and 1.0 mM for pure tributyrin and tributyrin emulsion, respectively. Both Caco-2 and HepG2 cells appeared to be slightly more sensitive to the treatment by tributyrin emulsion than pure tributyrin.
Competitive Uptake of Lipid Emulsion with LDL. The tributyrin emulsion prepared here has previously been proved to have the ability to bind to LDL in vitro . To determine the uptake mechanism of lipid emulsion by Caco-2 and HepG2 cells, the medium was added with increasing amounts of native LDL, while keeping the pure tributyrin or tributyrin emulsion concentration constant (the pure tributyrin or tributyrin emulsion concentration was kept at 0.75 and 1.0 mM in the Caco-2 and HepG2 cell culture medium, respectively). After incubation for 48 h, the viable cells were measured with MTT assay. In both cell lines, the addition of increasing amounts of native LDL progressively increased the percentage of viable cells treated with tributyrin emulsion (Fig. 6) . At the maximal concentration of LDL (100 g/ml), the viable cells reached over 92 and 77% for Caco-2 and HepG2 cells, respectively, whereas the addition of native LDL did not show any influence on the viability of the cells treated with pure tributyrin. The results suggest that competitive uptake existed between the emulsion and LDL uptake in Caco-2 and HepG2 cells. It may be noted that, in the absence of LDL, pure tributyrin and tributyrin emulsion had identical effect on the viability of Caco-2 cells (Fig. 6) . Thus, the mechanism involved in the uptake of pure tributyrin by Caco-2 cells might be as efficient as that through the LDL receptors. Another possibility is that tributyrin has very mild cytotoxic effect on colonic cancer cells. It first induced differentiation in colonic cancer cells before leading to their death from apoptosis (Schroder and Maurer, 2002) . The present growth inhibition system might not be sensitive enough to discern the selective uptake of the tributyrin emulsion by the Caco-2 cells from the pure tributyrin.
Discussion
The major goal in cancer chemotherapy is to selectively kill the tumor cells without damaging normal tissues and organs. Therefore, the achievement of vehicles capable of delivering drugs to targeted cells has long been pursued. In the last decades, several authors suggested the possibility of using of LDL to shuttle antitumor drugs to neoplastic cells, based on the increased expression of LDL receptor in certain types of cancer. Although it was successful in experimental trials, the difficulties in isolating LDL from plasma and handling the preparation are serious drawbacks for its use in routine treatment.
However, LDL-resembling emulsions can mimic the metabolism of plasma lipoprotein in vivo (Redgrave and Maranhã o, 1985; Redgrave et al., 1988; Maranhã o et al., 1994 Maranhã o et al., , 2002 Shawer et al., 2002) . Maranhã o et al. (1993) demonstrated in rats that such emulsion has a plasma kinetic behavior resembling that of native LDL and that the emulsion is probably taken up by the LDL receptor that sequester LDL into the cell. This type of emulsion normally is devoid of apoB, but it acquires LDL or apoE from the circulating lipoproteins after injection into the blood. Because LDL receptor can also recognize apoE, the emulsion is taken up by the tissues via the LDL receptor-mediated endocytic pathway. In patients with familial hypercholesterolemia, LDL-resembling emulsion plasma clearance was pronouncedly reduced compared with normal subjects (Roland et al., 1991) . This is also expected for native LDL, because LDL receptor is defective in this disease (Brown and Goldstein, 1986) . The lipid emulsion used here has been well characterized in our previous study . It consists of stable homogeneous spherical particles with a cholesteryl ester core surrounded by a phospholipid monolayer. We have previously shown that the lipid emulsion of tributyrin has the ability of binding to LDL in vitro; it is reasonable to assume that the emulsion may concentrate in tissues or organs with higher LDL receptor expression.
In the present investigations, we determined whether differences in pharmacokinetics exist between the lipid emulsion of tributyrin and that of pure tributyrin together with the influence of 17␣-ethynylestradiol on the pharmacokinetics of the emulsion. Between the emulsion and pure tributyrin, statistically significant differences in pharmacokinetic parameters calculated from both tributyrin and butyrate plasma concentrations were observed. Emulsion prepared in our study significantly enhanced the oral bioavailability of tributyrin. Both the oral administration and infusion of emulsion resulted in substantial higher concentrations of tributyrin and butyrate in plasma, which were maintained for at least 6 and 4 h, respectively. The pharmacokinetic parameters (clearance, distribution volume, and AUC) between healthy rats and rats treated with 17␣-ethynylestradiol also showed significant differences. The change in the balance process between emulsion and LDL generated a peak in the concentration-time profile in the emulsion-treated rats postinfusion. In our previous report, the emulsion binding with LDL was proved to be a reversible process . During infusion, part of emulsion infused bound with the overexpressed-LDL-receptor organs, such as liver. Post emulsion infusion, the drug would be released back to the blood circulation from these organs, as the blood concentration started to decline. Because the LDL receptors in treated rats have higher LDL receptor activity, the phenomenon of dissociation of drug from the binding sites leading to the appearance of a peak plasma concentration was not observed in these animals.
The elimination of butyrate and tributyrin was found nonlinear in this study. Egorin et al. (1999) also reported the saturable clearance and nonlinear pharmacokinetics of butyrate when using much higher doses of butyrate in both mice and rats, although the nonlinear nature of butyrate pharmacokinetics was less striking in rats. In their study, the very high concentration of butyrate (ϳ10 mM) in mice possibly saturated the activity site of enzyme for metabolizing butyrate, which caused the saturable clearance. Although the highest plasma butyrate concentration observed in this study was only about 1.8 mM, the tributyrin emulsion with affinity to LDL receptors might enhance the uptake and cause saturation at both the tissue binding site and clearance site, causing nonlinear pharmacokinetic profiles.
In vitro, tributyrin was reported to inhibit the growth of some tumor cells by inducing apoptosis and DNA synthesis arrest (Maier et al., 2000; Schroder and Maurer, 2002; Yan and Xu, 2003; Kuefer et al., 2004) . Although several pathways were reported, the molecular mechanisms by which tributyrin and/or its metabolite, butyrate, lead to a differentiated phenotype of tumor cells are still poorly understood (Heerdt et al., 1999; Guang et al., 2000; Clarke et al., 2001 ). The studies proposed modulation of nuclear functions, such as gene expression, acetylation of histones with altered chromatin conformation, and DNA cleavage of internucleosomal regions that are typical for apoptotic cells (Boffa et al., 1981; Heerdt et al., 1999) . In this study, the DNA fragmentation assay was applied to the cells treated with tributyrin or tributyrin emulsion. The observations suggested that, similar to the pure tributyrin, the tributyrin emulsion can also induce apoptosis in Caco-2 and HepG2 cell lines.
The physiologic role of the LDL receptor is to transport cholesterol-carrying lipoprotein particles into cells. The primary ligand for the receptor is LDL, which contains a single copy of apoB-100; approximately 65-70% of plasma cholesterol in humans circulates in the form of LDL. The LDL receptor also binds tightly to ␤-migrating forms of very lowdensity lipoprotein, which contains multiple copies of apoE. Receptor-ligand complexes enter the cell by endocytosis at clathrin-coated pits, where receptor molecules cluster on the cell surface. The N-terminal domain of the LDL receptor is the ligand-binding domain, and all other domains serve for internalization of the ligand bound to the receptor (Motley et al., 2003; Chung and Wasan, 2004; Ehrlich et al., 2004) . Bound lipoprotein particles are subsequently released in the low-pH milieu of the endosome, and the receptors then return to the cell surface in a process called receptor recycling (Davis et al., 1987; Rudenko et al., 2002) .
The current study provided the profiles of both butyrate and tributyrin in rats after oral administration and intravenous infusion of tributyrin emulsion. For the first time, the tributyrin concentration in plasma could be followed for up to 6 h after oral administration. Infusion of tributyrin emulsion provided another possible route of administration for studying the pharmacokinetics of tributyrin. The uptake mechanism of tributyrin emulsion was proven to be mediated, at least partially, by the LDL receptor pathway in Caco-2 and possibly also in HepG2 cell lines.
The limitations of this study was that only the pharmacokinetics and in vitro cell culture were studied. Investigation of the tissue distribution of labeled tributyrin would further clarify whether the tributyrin emulsion was actually delivered to the tissue and taken up through the LDL receptors.
